Tubulis Appoints Charles Fuchs as Chief Medical Officer

Tubulis Raises €308 Million Series C to Accelerate Clinical Development of TUB-040 and Expand Pipeline, led by Venrock Healthcare Capital Partners.

Tubulis Appoints Halley Gilbert as Chief Legal Officer and Chief Operating Officer

Tubulis Appoints Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc.

Launched Tubulis announces its drug candidate TUB-030 has entered clinical evaluation with the successful dosing of the first patient in the Phase I/IIa trial for advanced solid tumors.

Tubulis announces its drug candidate TUB-030 has entered clinical evaluation with the successful dosing of the first patient in the Phase I/IIa trial for advanced solid tumors.

Tubulis raised $138M in an upsized Series B2 financing led by EQT Life Sciences and Nextech Invest to advance clinical trials for lead ADC candidates and expand presence in the U.S.

Tubulis Closes €60 Million Series B Financing To Accelerate Its Adc Pipeline And Expand Its Breadth Of Platform Technologies

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving

Tubulis

Funding history

Recent signals